BPMC News and Press, Blueprint Medicines Corporation From 06/29/20

Burning Rock Biotech (NASDAQ: BNR ) announces a strategic partnership with CStone Pharmaceuticals ( OTCPK:CSPHF ) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines (NASDAQ: BPMC...

Sorrento Provides Positive Update for COVIDTRAP Sorrento Therapeutics Inc. ( SRNE ) announced completing the preclinical batch of COVIDTRAP protein. The company reported that it has obtained positive results from preclinical testing of the drug candidate STI-4398. Sorrento plans to devel...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...

Blueprint Medicines (NASDAQ: BPMC ) announces updated data from part 1 of a Phase 2 clinical trial, PIONEER , evaluating Ayvakit (avapritinib) in patients with indolent (slow-growing) systemic mastocytosis. The results were virtually presented at the European Academy of Allergy and Clinic...

CAMBRIDGE, Mass. , June 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced updated clinical data from part 1 of the PIONEER trial showing robust...

CAMBRIDGE, Mass. , June 3, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on June 1, 2020 , the Compensation Committee of...

CAMBRIDGE, Mass. , May 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from the ongoing ARROW clinical trial of pralsetinib in pat...

CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced its participation in the following upcoming inves...

CAMBRIDGE, Mass. , May 26, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that it will host a live conference call and webc...

Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...